The nation of Zimbabwe has rejected a major American health deal valued at $367m (272 million pounds) over five years because of the United States' request for confidential data.
This move came to light after a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
An official representative has since stated that the US was seeking health data for scientific study and commercial purposes while refused to guarantee the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged further negotiations to reach a deal agreeable to all parties so the nation's vital HIV treatment initiative can continue.
Wider Background
This rejection comes after a similar situation in Kenya, where a high court blocked a related health funding agreement after concerns were filed about the safety of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen aid for the US government, but Trump stated its spending was "wasteful" and his administration was pursuing direct bilateral deals to boost transparency and responsibility.
According to statements, Sixteen nations in Africa have so far signed these new health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership might have yielded extraordinary benefits for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data indefinitely, without any corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"In essence, our nation would provide the raw materials for scientific discovery without any assurance that the resulting innovations would be accessible to our citizens if a new health crisis arise."
National Interest and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures already set up via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system designed to manage future global health emergencies.
"This system is intended to ensure that when a country provides its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the capability to develop them."
These objections over the US deal "must not be interpreted as opposition to America," he added.
"We are open to continued discussions with our American counterparts on how future collaboration could be designed in a way that respects the sovereignty and interests of each country."
Medical Community Response
Medical experts expressed it acknowledged the official position, but urged that negotiations should continue given that much of the country's HIV programmes depended on international support.
"If technical issues arise, including those involving information security or implementation frameworks, these can often be addressed via technical clarification and mutually agreed protections," the group said.
The halted deal underscores the ongoing challenges between receiving vital foreign assistance and protecting national sovereignty in an increasingly data-driven world.